AiTan (rivoceranib) / Jiangsu Hengrui Pharma, HLB Bio Group, Bukwang Pharma, Advenchen - LARVOL DELTA

Efficacy and Safety of Camrelizumab and Apatinib in Combination with IMRT in Unresectable Hepatocellular Carcinoma: A Non-Randomised Phase 2 Study (ASTRO 2025) - No abstract available

Clinical • Combination therapy • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Efficacy and Safety of Cross-Line Adebrelimab Combined With Apatinib and Nab-Paclitaxel in Recurrent Small Cell Lung Cancer (IASLC-WCLC 2025) - "Introduction : Treatment options for relapsed small cell lung cancer (SCLC) remain limited, with second-line standard regimens (e.g., topotecan) demonstrating an objective response rate (ORR) of <25% and a median overall survival (OS) of 6-8 months. The CAPSTONE-1 study established adebrelimab combined with carboplatin and etoposide as the first-line standard of care for patients with extensive-stage SCLC in China...Patients received induction therapy comprising adebrelimab (1200 mg q3w), apatinib (250 mg qd), and nab-paclitaxel (200 mg/m2 q3w) for 2-4 cycles, followed by maintenance therapy with adebrelimab and apatinib until disease progression or intolerable toxicity. The primary endpoint was ORR, the secondary endpoints included PFS, OS, disease control rate (DCR),duration of response and safety assessed by CTCAE v5.0."

Clinical • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Phase II Study of Firmonertinib Combined With Apatinib as First-Line Therapy in NSCLC Patients With EGFR Uncommon Mutations (IASLC-WCLC 2025) - "Although afatinib or osimertinib as preferred first-line therapy options have been recommended for the treatment of non-small cell lung cancer (NSCLC) with EGFR uncommon mutations, patients' therapeutic demands are far from being met. No treatment-related deaths were reported. Conclusions : Firmonertinib combined with apatinib demonstrated promising antitumor activity and a manageable safety profile for metastatic non-small cell lung cancer with EGFR uncommon mutations."

Clinical • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR

TASK-05: HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) (clinicaltrials.gov) - P2 | N=45 | Recruiting | Sponsor: Fudan University | Not yet recruiting ➔ Recruiting

Enrollment open • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Oncology • Solid Tumor

The U.S. Food and Drug Administration (FDA) has officially disclosed the reasons for withholding approval of HLB’s liver cancer treatment "Rivoceranib" (Business Korea) - "According to industry sources on Sept. 10, the FDA published a Complete Response Letter (CRL) on its website regarding the combination therapy of Rivoceranib and Chinese Hengrui Pharmaceuticals’ immunotherapy drug 'Camrelizumab'. The FDA stated that approval would only be possible if the two drugs were reviewed together....FDA made it clear that standalone approval for Rivoceranib would not be possible as long as Camrelizumab has not received formal approval in the United States. Furthermore, the FDA cited incomplete bioresearch monitoring (BIMO) inspections at some clinical trial sites....HLB...aiming to reapply within this year."

CRL • Hepatocellular Cancer

Perioperative Camrelizumab plus Rivoceranib in Resectable Hepatocellular Carcinoma (CARES-009): A Randomized, Multicenter, Phase 3 Trial (ESMO 2025) - No abstract available

Clinical • P3 data • Hepatocellular Cancer • Oncology • Solid Tumor

Effectiveness and Safety of Camrelizumab Plus Rivoceranib Combined With TACE With or Without HAIC in First-Line Treatment of Unresectable Hepatocellular Carcinoma (ESMO 2025) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

HCC-IM-1: Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment (clinicaltrials.gov) - P=N/A | N=150 | Not yet recruiting | Sponsor: Fudan University

New trial • Hepatocellular Cancer • Oncology • Solid Tumor

A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data (clinicaltrials.gov) - P=N/A | N=2000 | Not yet recruiting | Sponsor: Xuhua Duan

Heterogeneity • IO biomarker • New trial • Real-world evidence • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

The synergistic potential of camrelizumab and rivoceranib in advanced hepatocellular carcinoma: a review of current evidence. (PubMed, Ann Med Surg (Lond)) - "The final analysis of CARES-310 demonstrated a median overall survival (OS) of 23.8 months with camrelizumab plus rivoceranib, significantly higher than the 15.2 months observed with sorafenib (HR, 0.64; 95% CI, 0.52-0.79; P < 0.0001). With a manageable safety profile and significant survival benefits, camrelizumab plus rivoceranib represents a major advancement in HCC treatment. Ongoing research will further define its role in clinical practice and optimize outcomes for patients with limited treatment options."

Journal • Review • Hepatocellular Cancer • Oncology • Solid Tumor

PD-1 Inhibitors Combined With Targeted Therapy With or Without Interventional Therapy for Advanced HCC (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Peking Union Medical College Hospital

New P2 trial • Hepatocellular Cancer • Oncology • Solid Tumor

FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov) - P2 | N=716 | Recruiting | Sponsor: Fudan University | Trial completion date: Sep 2025 ➔ Sep 2028 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD8 • FOXC1 • HER-2 • PGR

Efficacy and Safety of Camrelizumab Plus Apatinib for Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-analysis. (PubMed, Am J Clin Oncol) - "Camrelizumab plus apatinib has shown promising efficacy with improved OS, PFS, and response rates. Large-scale trials are warranted to validate these findings and optimize treatment strategies."

Journal • Retrospective data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Hematological Disorders • Leukopenia • Neutropenia • Oncology • Squamous Cell Carcinoma • Thrombocytopenia

Safety and Efficacy of Camrelizumab Combined With Apatinib for Advanced Gastric Cancer: A Systematic Review and Meta-Analysis (ACG 2025) - "564 patients from 14 studies were included in the analysis. The pooled 1-year overall survival (OS) from 8 studies was 61% (95% CI: 45–75; I² = 81.4%), with significantly higher OS of 74% (60–86; p = 0.0092; I² = 63.5%) in the treatment-naïve subgroup compared to the pretreated subgroup [45% (29–62; I² = 63.1%). The pooled 1-year progression-free survival was 22% (6–45; I² = 88.3%."

Metastases • Retrospective data • Review • Dermatology • Gastric Cancer • Leukopenia • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia

Efficacy and Safety of Camrelizumab Plus Apatinib for Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis (ACG 2025) - "The pooled 1-year overall survival (OS) from 6 studies was 71% (95% CI: 50 – 89%; I2 = 94.1%), with treatment naïve patients showing a statistically higher 1-year OS of 95% (95% CI: 90 – 98%; I2 = 0%) than 55% (95% CI: 41 – 69; p-value < 0.0001; I2 = 75.7%) in pretreated patients. 1-Year progression-free survival (PFS) was 25% (13 – 39; I2 = 72.5%) across 4 studies. Overall response rate was significantly higher in the treatment-naïve group [87% (95% CI: 80 – 93); I2 = 14%] than the previously treated group [28% (95% CI: 18 – 40); I2 = 72.5%]."

Retrospective data • Review • Anemia • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Hematological Disorders • Leukopenia • Neutropenia • Oncology • Squamous Cell Carcinoma • Thrombocytopenia

Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=27 | Recruiting | Sponsor: Wei Zhang

New P2 trial • Hepatocellular Cancer • Oncology • Solid Tumor

Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma. (PubMed, Clin Cancer Res) - P1 | "The combination of M1-c6v1 with camrelizumab and apatinib demonstrates an acceptable safety profile and promising efficacy in advanced HCC."

Journal • Hematological Disorders • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Influenza • Oncology • Respiratory Diseases • Solid Tumor

Clinical benefit of camrelizumab (cam) + rivoceranib (rivo) in unresectable hepatocellular carcinoma (uHCC) patients with macrovascular invasion (MVI) and extrahepatic spread (EHS), CARES-310 (ESMO 2025) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Neoadjuvant therapy of sequential transcatheter arterial chemoembolization, camrelizumab and apatinib for single large hepatocellular carcinoma (NEO-START): A randomized controlled trial (ESMO 2025) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Study of combination of camrelizumab and apatinib for the neoadjuvant treatment of TNBC with TILs>10% (ChiCTR) - P2 | N=58 | Recruiting | Sponsor: Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University

New P2 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

Apatinib Reverses Tamoxifen Resistance in ER+ Breast Cancer via the VEGFR2/ERα/PI3K/Akt Pathway (ESMO 2025) - No abstract available

Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • KDR

Adebrelimab Plus Apatinib in Advanced Esophageal Squamous Cell Carcinoma Following Immune Checkpoint Inhibitors: Preliminary Results from Cohort 3 of CAP 02 Study (ESMO 2025) - No abstract available

Checkpoint inhibition • Metastases • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Adebrelimab plus Apatinib and Etoposide in the Treatment of HER2-Negative Breast Cancer Brain Metastasis: A Phase II Study (ESMO 2025) - No abstract available

P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Comparative effectiveness and safety of second-line therapies and dosing regimens for advanced hepatocellular carcinoma: a network meta-analysis. (PubMed, Eur J Gastroenterol Hepatol) - "Brivanib 800 mg once daily (OD) was most effective in terms of ORR [odds ratio (OR) = 7.13, 95% CI = 1.42, 35.88], while apatinib 750 mg QD ranked highest for DCR (OR = 3.92, 95% CI = 1.76, 8.71). Codrituzumab 1600 mg administered every 2 weeks demonstrated the most advantageous health profile, markedly decreasing AEs and instances of grade 3-4 AEs...Cabozantinib 60 mg QD and pembrolizumab 200 mg Q3W arise as the most suitable second-line therapies alternatives for advanced HCC, offering substantial improvements in survival and disease control with manageable adverse effects. These findings support the integration of both targeted and immune therapies in handling of advanced HCC."

HEOR • Journal • Retrospective data • Hepatocellular Cancer • Oncology • Solid Tumor

Fuzuloparib (FZPL) monotherapy or in combination with apatinib (APA) as first-line (1L) maintenance therapy in advanced ovarian cancer (OC): final analysis of the FZOCUS-1 trial (ESMO 2025) - No abstract available

Clinical • Combination therapy • Metastases • Monotherapy • Oncology • Ovarian Cancer • Solid Tumor